{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Méglutol : Questions médicales les plus fréquentes",
"headline": "Méglutol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Méglutol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-12",
"dateModified": "2025-03-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Méglutol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Glutarates",
"url": "https://questionsmedicales.fr/mesh/D005977",
"about": {
"@type": "MedicalCondition",
"name": "Glutarates",
"code": {
"@type": "MedicalCode",
"code": "D005977",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.241.081.337.351"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Méglutol",
"alternateName": "Meglutol",
"code": {
"@type": "MedicalCode",
"code": "D015093",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Marvin N Iman",
"url": "https://questionsmedicales.fr/author/Marvin%20N%20Iman",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Graduate School of Engineering, Osaka University, Japan."
}
},
{
"@type": "Person",
"name": "Danielle E Haslam",
"url": "https://questionsmedicales.fr/author/Danielle%20E%20Haslam",
"affiliation": {
"@type": "Organization",
"name": "Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Liming Liang",
"url": "https://questionsmedicales.fr/author/Liming%20Liang",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Kai Guo",
"url": "https://questionsmedicales.fr/author/Kai%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Center for Clinical Research and Health Promotion, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, Puerto Rico, USA."
}
},
{
"@type": "Person",
"name": "Kaumudi Joshipura",
"url": "https://questionsmedicales.fr/author/Kaumudi%20Joshipura",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Center for Clinical Research and Health Promotion, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, Puerto Rico, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The microbiota of sexual intercourse and its effect on prostatitis.",
"datePublished": "2024-03-30",
"url": "https://questionsmedicales.fr/article/38735876",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.22514/j.androl.2024.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Chronic prostatitis/chronic pelvic pain syndrome].",
"datePublished": "2023-04-30",
"url": "https://questionsmedicales.fr/article/37120786",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00120-023-02089-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is type III prostatitis also associated with bacterial infection?",
"datePublished": "2023-07-03",
"url": "https://questionsmedicales.fr/article/37465760",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcimb.2023.1189081"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Microbial etiology of bacterial chronic prostatitis: systematic review].",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36622055",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.37201/req/099.2022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate Infiltration by Treg and Th17 Cells as an Immune Response to",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/36012113",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23168849"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Acides carboxyliques",
"item": "https://questionsmedicales.fr/mesh/D002264"
},
{
"@type": "ListItem",
"position": 4,
"name": "Acides acycliques",
"item": "https://questionsmedicales.fr/mesh/D000144"
},
{
"@type": "ListItem",
"position": 5,
"name": "Diacides carboxyliques",
"item": "https://questionsmedicales.fr/mesh/D003998"
},
{
"@type": "ListItem",
"position": 6,
"name": "Glutarates",
"item": "https://questionsmedicales.fr/mesh/D005977"
},
{
"@type": "ListItem",
"position": 7,
"name": "Méglutol",
"item": "https://questionsmedicales.fr/mesh/D015093"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Méglutol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Méglutol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Méglutol",
"description": "Comment diagnostiquer un besoin de Méglutol ?\nQuels tests sont utilisés pour le diabète ?\nQuand envisager le Méglutol ?\nQuels signes indiquent un diabète avancé ?\nLe Méglutol est-il prescrit pour tous les diabétiques ?",
"url": "https://questionsmedicales.fr/mesh/D015093?mesh_terms=Prostatitis&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Méglutol",
"description": "Quels symptômes le Méglutol aide-t-il à réduire ?\nLe Méglutol provoque-t-il des effets secondaires ?\nComment reconnaître une hypoglycémie ?\nLe Méglutol affecte-t-il le poids ?\nQuels sont les signes d'une réaction allergique ?",
"url": "https://questionsmedicales.fr/mesh/D015093?mesh_terms=Prostatitis&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Méglutol",
"description": "Comment prévenir le diabète de type 2 ?\nLe Méglutol peut-il être utilisé préventivement ?\nQuels modes de vie favorisent la santé métabolique ?\nLes contrôles réguliers de la glycémie sont-ils importants ?\nComment le stress influence-t-il le diabète ?",
"url": "https://questionsmedicales.fr/mesh/D015093?mesh_terms=Prostatitis&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Méglutol",
"description": "Comment le Méglutol est-il administré ?\nPeut-on combiner le Méglutol avec d'autres médicaments ?\nQuelle est la posologie habituelle du Méglutol ?\nLe Méglutol nécessite-t-il un suivi médical ?\nQuels sont les objectifs du traitement avec Méglutol ?",
"url": "https://questionsmedicales.fr/mesh/D015093?mesh_terms=Prostatitis&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Méglutol",
"description": "Quelles sont les complications du diabète non contrôlé ?\nLe Méglutol réduit-il les risques de complications ?\nComment prévenir les complications du diabète ?\nLes complications peuvent-elles être réversibles ?\nQuels examens sont nécessaires pour détecter les complications ?",
"url": "https://questionsmedicales.fr/mesh/D015093?mesh_terms=Prostatitis&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Méglutol",
"description": "Quels sont les principaux facteurs de risque du diabète ?\nLe stress est-il un facteur de risque ?\nL'alimentation influence-t-elle le risque de diabète ?\nL'âge est-il un facteur de risque pour le diabète ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D015093?mesh_terms=Prostatitis&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un besoin de Méglutol ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic de diabète de type 2 est établi par des tests de glycémie et d'insuline."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diabète ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la glycémie à jeun, l'HbA1c et le test de tolérance au glucose."
}
},
{
"@type": "Question",
"name": "Quand envisager le Méglutol ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est envisagé lorsque les changements de mode de vie ne suffisent pas à contrôler la glycémie."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un diabète avancé ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une soif excessive, des mictions fréquentes et une fatigue persistante."
}
},
{
"@type": "Question",
"name": "Le Méglutol est-il prescrit pour tous les diabétiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est principalement prescrit pour les patients avec un diabète de type 2 non contrôlé."
}
},
{
"@type": "Question",
"name": "Quels symptômes le Méglutol aide-t-il à réduire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il aide à réduire les symptômes liés à l'hyperglycémie, comme la soif et la fatigue."
}
},
{
"@type": "Question",
"name": "Le Méglutol provoque-t-il des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires peuvent inclure des nausées, des diarrhées et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hypoglycémie ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des sueurs, des tremblements, de la confusion et une faim intense."
}
},
{
"@type": "Question",
"name": "Le Méglutol affecte-t-il le poids ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut entraîner une légère perte de poids chez certains patients, mais pas chez tous."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une réaction allergique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des éruptions cutanées, des démangeaisons et un gonflement du visage."
}
},
{
"@type": "Question",
"name": "Comment prévenir le diabète de type 2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et le maintien d'un poids santé sont essentiels."
}
},
{
"@type": "Question",
"name": "Le Méglutol peut-il être utilisé préventivement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est utilisé pour traiter le diabète déjà établi, pas pour la prévention."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent la santé métabolique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activité physique régulière, une alimentation riche en fibres et une hydratation adéquate."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers de la glycémie sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à détecter les anomalies précocement et à ajuster le traitement si nécessaire."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il le diabète ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut augmenter la glycémie, rendant le contrôle du diabète plus difficile."
}
},
{
"@type": "Question",
"name": "Comment le Méglutol est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement pris par voie orale, souvent avant les repas pour maximiser son efficacité."
}
},
{
"@type": "Question",
"name": "Peut-on combiner le Méglutol avec d'autres médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être combiné avec d'autres antidiabétiques pour un meilleur contrôle glycémique."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie habituelle du Méglutol ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie, mais commence souvent à 0,5 mg à 1 mg par jour, ajustée selon les besoins."
}
},
{
"@type": "Question",
"name": "Le Méglutol nécessite-t-il un suivi médical ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quels sont les objectifs du traitement avec Méglutol ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'objectif est de maintenir une glycémie normale et de prévenir les complications du diabète."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du diabète non contrôlé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies cardiovasculaires, des neuropathies et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Le Méglutol réduit-il les risques de complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon contrôle glycémique avec Méglutol peut réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications du diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier, une bonne hygiène de vie et un contrôle glycémique strict sont essentiels."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et un bon contrôle."
}
},
{
"@type": "Question",
"name": "Quels examens sont nécessaires pour détecter les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers des yeux, des reins et des pieds sont recommandés pour détecter les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du diabète ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, l'inactivité physique, l'âge et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à l'augmentation de la glycémie et au diabète."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de diabète ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en sucres et en graisses augmente le risque de diabète de type 2."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour le diabète ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de diabète augmente avec l'âge, surtout après 45 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des membres de la famille atteints de diabète augmente le risque personnel."
}
}
]
}
]
}
It is estimated that microorganisms colonize 90% of the body surface. In some tracts, such as the genitourinary tract, the microbiota varies throughout life, influenced by hormonal stimulation and sex...
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is defined as chronic pain or discomfort in the pelvic region for at least 3 of the past 6 months. It is variably associated with lower urina...
To explore whether type III prostatitis is related to bacterial infection by detecting the composition and function of microorganisms in expressed prostatic secretion (EPS) of patients with chronic pr...
According to the inclusion and exclusion criteria, 57 subjects were included in our study, divided into the healthy group, type II prostatitis group, and type III prostatitis group. 16s rRNA sequencin...
Many microorganisms exist in EPS in both CP patients and healthy populations. However, the relative abundance of...
Based on our sequencing results and previous studies, we suggest that type III prostatitis may also be caused by bacterial infection....
The importance of Gram-positive microorganisms and atypical bacteria in chronic bacterial prostatitis (CBP) has recently been described. For this reason, this study analyzes the etiology of CBP, as we...
A systematic review of studies obtained through the MEDLINE (PubMed) database, related to the etiology and antibiotic resistance profile of CBP, published up July 1, 2021....
The most frequent isolated microorganisms that we have found in publications are Enterococcus faecalis (46.90%), Staphylococcus spp. (22.30%), Escherichia coli (15.09%) and atypical bacteria (6.04%)....
CBP is undergoing and unprecedented change of paradigm. Gram-positive bacteria and atypical bacteria are the main pathogens involved in the aetiology of this entity. This forces us to rethink the ther...
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) belong to the most frequent diseases in ageing men. It has been proposed that prostate chronic inflammation is a risk factor for the develo...
Men using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and prospective cohort studies. Stat...
We summarise epidemiological data from studies of statins and prostate cancer and discuss to what extent these findings can be interpreted as causal. Additionally, lipid-mediated and non-lipid-mediate...
Data from prospective observational studies generally reported a lower risk of fatal prostate cancer among statin users. There is some evidence for serum cholesterol-lowering as an indirect mechanism ...
Prospective and registry-based studies support a lower risk of advanced and fatal prostate cancer in statin users relative to non-users, as well as better outcomes among prostate cancer patients. The ...
Ductal epithelial changes (lympho-epithelial lesions-LEL) in prostatic chronic inflammation (CI) are not well studied so far....
to investigate LEL immediately adjacent to prostatic CI....
We studied LEL in 144 prostatic surgical and autopsy specimens in various types of prostatic CI: NIH-category IV prostatitis (histologic prostatitis-HP), nonspecific granulomatous prostatitis (NSGP), ...
LEL was identified in all types of prostatic specimens and in all types of prostatic CI: in 70.9% of patients with HP; in 100% of cases with NSGP; in 68.7% and in 80% adjacent to BPH and PCa respectiv...
The study presents the first attempt to examine LEL in inflammatory human prostate. PD-L1 positive LEL have no diagnostic organ specificity, although they are a constant histological finding in HG pro...
Urinary microbiota is implicated in many diseases of the urinary tract. The aim of this study was to perform a systematic review of the role of urinary microbiota in prostatic diseases....
A PubMed/Medline search was undergone from inception through June 2022 for studies investigating urinary microbiota alterations in prostatic diseases, subdivided into benign prostatic hyperplasia (BPH...
A total of 16 studies (4 studies on BPH, 9 studies on PCa and 3 studies on CP) comprising 1486 patients were included in our final analysis. Patients with BPH had a different urinary microbial composi...
Urinary microbiota is implicated in prostatic diseases, especially in BPH, PCa and CP. However, given the relative heterogeneity among published studies, this implication suggests better delineation i...
Chronic prostatitis (CP) can impair health-related quality of life (QOL), but the full impact of CP, including the impact of CP-like symptoms in men who have no CP diagnosis (CPS), is unknown. We esti...
From a representative nationwide survey of men aged 20-84 in Japan, we determined the prevalence of DCP and also of CPS. For CPS, we used Nickel's criteria, which were used previously to estimate the ...
Among the 5 010 participants, 1.4% had DCP and 3.7% had CPS. The sensitivity analyses resulted in CPS prevalence estimates of 3.1% and 4.5%. CPS was particularly common in younger participants (5.7% o...
CP is common, but it is underdiagnosed, particularly in younger men. Whether diagnosed or only suspected, CP's impact on QOL is large. Because CP is common, and because it substantially impairs indivi...
We developed a simple self-checkable screening tool for chronic prostatitis (S-CP) and internally validated it to encourage men (in the general population) with possible chronic prostatitis to consult...
The expert panel proposed the S-CP, which comprises three domains: Area of pain or discomfort (6 components), accompanying Symptom (6 components), and Trigger for symptom flares (4 components). We emp...
Data were collected for 5,010 men-71 (1.4%) had a chronic prostatitis diagnosis. The apparent and adjusted area under the curve for the S-CP was 0.765 [95% confidence interval (CI) 0.702, 0.829] and 0...
The reasonable predictive performance of the S-CP indicated that patients (in the general population) with chronic prostatitis were screened as a first step. Further research would develop another too...